<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749684</url>
  </required_header>
  <id_info>
    <org_study_id>P04083</org_study_id>
    <nct_id>NCT00749684</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)</brief_title>
  <official_title>Efficacy and Safety of High-dose Treatment With the Immunomodulator Interferon-α-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational study is to document the efficacy and tolerability of high-dose
      interferon therapy in adult participants with malignant melanoma at high risk of relapse and
      to compare them with the survival times and relapse rates in previous studies (historical
      control).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational study to evaluate the tolerability and efficacy (vs historical controls) of a
      high-dose therapy scheme with interferon-α-2b (IntronA®):

      Adjuvant treatment with interferon-α-2 has been demonstrated in a number of studies to have
      an antiproliferative effect on malignant melanoma. In these cases a response rate of up to
      20% could be achieved with a dose of 10 million IU or more 3x/week or daily. Kirkwood et al.
      showed in a study carried out in ECOG (the Eastern Cooperative Oncology Group, study no.
      1684) that there was a clear and significant survival advantage versus the observation group
      with the following dose:

      20 mio IU/m² interferon-α-2b (IntronA®) 5x/week iv over the course of one month followed by
      11 months with 10 mio IU/m² 3x/week sc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Disease Recurrence</measure>
    <time_frame>Throughout 12 months of treatment and 24 months of follow-up</time_frame>
    <description>Number of participants with disease recurrence was being measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse Free Survival Time</measure>
    <time_frame>Throughout 12 months of treatment and 24 months of follow-up</time_frame>
    <description>Median time to recurrence according to Kaplan Maier evaluation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">138</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Adults with malignant melanoma at high risk of relapse</arm_group_label>
    <description>Adults with malignant melanoma of the following stages:
II and III (&gt;/= 1.5 mm Breslow thickness without distant metastases
melanoma with lymph node metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interferon α-2b</intervention_name>
    <description>20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.</description>
    <arm_group_label>Adults with malignant melanoma at high risk of relapse</arm_group_label>
    <other_name>Intron A</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants in Austria with malignant melanoma at high risk of relapse
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female participants

          -  Age 18-70 years

          -  Malignant melanoma stage II or III (&gt;/= 1.5 mm tumor thickness, no distant metastases
             or Malignant melanoma with lymph node metastases or Lymph node metastases with unknown
             primary tumor

          -  An excision border of at least 2 cm around the primary tumor

          -  Therapy must start within 12 weeks after surgery of the tumor/of the lymph node
             metastases

          -  ECOG status 0-1 (= Karnofsky Index &gt;/= 80)

          -  Laboratory parameters

               -  Hematocrit &gt;= 33%

               -  Leukocytes &gt;= 3000/μl

               -  Thrombocytes &gt;= 100000/μl

               -  Alanine aminotransferase(ALT) &lt;= 2x normal values

               -  Bilirubin &lt;= 2x normal values

        Exclusion Criteria:

          -  Known allergy to one of the medications or any of its component parts

          -  Refusal on the part of participants capable of childbearing to use a reliable
             contraceptive

          -  Lactating mothers

          -  Presence of distant metastases

          -  Another primary tumor of different histological origin than corresponding to the
             indication (except when the relapse-free interval is &gt; 5 years, or the tumor is a
             cervical carcinoma in situ, a basal cell carcinoma or cutaneous squamous cell
             carcinoma)

          -  Participants on corticosteroid treatment or treatment with an immunomodulating
             substance

          -  Preexisting psychiatric illness, particularly serious depression

          -  Prior adjuvant radio-, chemo-, or immuno-therapy

          -  Treatment with an investigational drug within the prior 30 days

          -  Participant history that includes cardiac arrhythmia, cardiac insufficiency requiring
             treatment, or anthracycline administration

          -  Myocardial infarction within the prior year

          -  An unstable medical condition (apart from the indication) that in the judgment of the
             investigating physician excludes the participants from the study

          -  Psoriasis (a relative exclusion criterion, since interferon can aggravate psoriasis;
             decision to be based on risk/benefit analysis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <results_first_submitted>October 22, 2010</results_first_submitted>
  <results_first_submitted_qc>February 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2011</results_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interferon-alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male and female participants, with malignant melanoma Stage II or III (&gt;1.5 mm tumor thickness, no distant metastasis) or malignant melanoma with evidence of lymph node metastis or lymph node metastasis of malignant melanoma at unknown primary tumor, primary tumor has to be surgically resected within 2 months after first biopsy/excision.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adults With Malignant Melanoma at High Risk of Relapse</title>
          <description>Adults with malignant melanoma of the following stages:
II and III (&gt;/= 1.5 mm Breslow thickness without distant metastases
melanoma with lymph node metastases</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant's Wish</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Documented</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Desease</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Therapy according to protocol + AE</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE+discontinuation on participants wish</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adults With Malignant Melanoma at High Risk of Relapse</title>
          <description>Adults with malignant melanoma of the following stages:
II and III (&gt;/= 1.5 mm Breslow thickness without distant metastases
melanoma with lymph node metastases</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.83" spread="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.15" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.27" spread="12.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="12.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Disease Recurrence</title>
        <description>Number of participants with disease recurrence was being measured.</description>
        <time_frame>Throughout 12 months of treatment and 24 months of follow-up</time_frame>
        <population>138 participants with malignant melanoma, 88 male participants and 50 female participants were evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults With Malignant Melanoma at High Risk of Relapse</title>
            <description>Adults with malignant melanoma of the following stages:
II and III (&gt;/= 1.5 mm Breslow thickness without distant metastases
melanoma with lymph node metastases</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disease Recurrence</title>
          <description>Number of participants with disease recurrence was being measured.</description>
          <population>138 participants with malignant melanoma, 88 male participants and 50 female participants were evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relapse Free Survival Time</title>
        <description>Median time to recurrence according to Kaplan Maier evaluation</description>
        <time_frame>Throughout 12 months of treatment and 24 months of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adults With Malignant Melanoma at High Risk of Relapse</title>
            <description>Adults with malignant melanoma of the following stages:
II and III (&gt;/= 1.5 mm Breslow thickness without distant metastases
melanoma with lymph node metastases</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Free Survival Time</title>
          <description>Median time to recurrence according to Kaplan Maier evaluation</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" lower_limit="0" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Interferon Alfa-2b</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SARCOIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA EFFLUVIUM</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp and Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>clinicaltrialsdisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

